ABL1 and acute lymphoblastic leukemia: In particular, the association of imatinib or new ABL-kinase inhibitors with drugs that enhances PP2A phosphatase activity may represent a successful therapeutic strategy for CML blast crisis patients that are nonresponsive or develop resistance to imatinib and, perhaps, for those patients with Ph1 ALL.